Nature Medicine Publishes Phase 3 OUTSTAND-2: Hengrui's Oral GLP-1 Pill Safiglipron Matches Dapagliflozin on HbA1c, and Its Top Dose Beats It
Full results of OUTSTAND-2, published in Nature Medicine on Monday, October 5, 2026, come from 810 adults in China with type 2 diabetes not controlled on metformin, randomized to once-daily safiglipron (HRS-7535) 30, 60, or 90 mg or the SGLT2 inhibitor dapagliflozin 10 mg for 32 weeks. HbA1c fell 0.22 to 0.40 percentage points more on safiglipron, meeting the non-inferiority goal at every dose, and the 90 mg dose also passed the superiority test; weight loss was similar (2.35% to 4.17% on safiglipron versus 3.60% on dapagliflozin). Gastrointestinal side effects were more common on safiglipron, 3.9% to 4.0% stopped for adverse events versus 1.5% on dapagliflozin, Hengrui funded the trial, whose topline results were announced in July.